SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare surges on getting USFDA’s approval for Imatinib Mesylate Tablets

18 Jan 2019 Evaluate

Shilpa Medicare is currently trading at Rs. 404.15, up by 9.05 points or 2.29% from its previous closing of Rs. 395.10 on the BSE.

The scrip opened at Rs. 397.75 and has touched a high and low of Rs. 409.90 and Rs. 397.75 respectively. So far 583 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 605.00 on 23-Jan-2018 and a 52 week low of Rs. 357.95 on 23-Jul-2018.

Last one week high and low of the scrip stood at Rs. 398.70 and Rs. 381.05 respectively. The current market cap of the company is Rs. 3242.73 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 32.16% and 14.04% respectively.

Shilpa Medicare has received the US Food and Drug Administration (USFDA) approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg on January 17, 2019.

Imatinib Mesylate Tablets is a generic equivalent of the reference listed drug (RLD), gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended in the label approved by FDA.

According to IQVIA MAT Q2 2018 data, the US market for Imatinib Mesylate Tablets, 100 mg and 400 mg is approximately $885 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×